Is Real-World Evidence on Acquired Resistance to Osimertinib Relevant Clinically?

J Thorac Oncol. 2024 Feb;19(2):187-189. doi: 10.1016/j.jtho.2023.11.003.

Author

Jih-Hsiang Lee¹

Affiliation

¹ Department of Oncology, National Taiwan University Hospital, Hsin-Chu Branch, Hsinchu City, Taiwan; Department of Oncology, National Taiwan University Hospital, Taipei City, Taiwan; Graduate Institute of Oncology, National Taiwan University, Taipei City, Taiwan. Electronic address: leejihhsiang@ntu.edu.tw.

PMID: 38325976
DOI: 10.1016/j.jtho.2023.11.003

No abstract available

Publication types

Editorial
Comment

MeSH terms

Acrylamides / pharmacology
Aniline Compounds / pharmacology
Carcinoma, Non-Small-Cell Lung* / drug therapy
Drug Resistance, Neoplasm
Humans
Indoles*
Lung Neoplasms* / drug therapy
Mutation
Protein Kinase Inhibitors / pharmacology
Protein Kinase Inhibitors / therapeutic use
Pyrimidines*

Substances

osimertinib
Acrylamides
Aniline Compounds
Protein Kinase Inhibitors
Indoles
Pyrimidines